WebOct 21, 2016 · Sunovion Pharmaceuticals Inc. and Cynapsus Therapeutics Inc. announced that Sunovion has completed, through its wholly owned subsidiary, Sunovion CNS Development Canada ULC, the previously announced acquisition of Cynapsus. The acquisition is aligned with Sunovion’s global strategy to expand and diversify its portfolio … WebJun 19, 2015 · Cynapsus Therapeutics Inc. long-awaited U.S. initial public offering is set to close early next week. The company recently announced that it plans to offer 4.5 million shares of common stock at a ...
Cynapsus Therapeutics Inc.: Cynapsus Therapeutics Awarded …
WebSep 25, 2014 · Save Article Canadian Small Cap Stock Universe for Wednesday, September 24, 2014 Based on proprietary criteria, Ubika Research found that the top small cap stock gainers from each of the listed sectors performed as follows: • Diversified Mining: Mkango Resources Ltd (TSXV: MKA) with a 77% gain • Energy: Strategic Oil & Gas Ltd … WebCynapsus Therapeutics Inc. is a specialty pharmaceutical company developing a drug to treat the motor symptoms of Parkinson's disease. Based in Toronto, Ontario, Canada. … sifted sweets
Cynapsus Therapeutics : Provides Clinical and Regulatory Update
WebJun 23, 2024 · He was most recently, the co-inventor, Chief Executive Officer and Director of Cynapsus Therapeutics, a NASDAQ listed specialty pharmaceutical company that developed the first successful sublingual apomorphine thin film strip for Parkinson’s disease. The drug today known as Kynmobi was approved for commercialization by the United … WebPhone Number 416-703-2449. Cynapsus is a pharmaceutical company that focuses on developing a non-injectable drug for Parkinson’s disease. … WebAug 8, 2012 · Cynapsus is a specialty pharmaceutical company developing an improved dosing formulation of an approved drug used to treat the symptoms of Parkinson's disease. Over one million people in the... the practicum and the internship are types of